ENC1 - Overview: Encephalopathy, Autoimmune Evaluation, Spinal Fluid

Test Catalog

Test Name

Test ID: ENC1    
Encephalopathy, Autoimmune Evaluation, Spinal Fluid

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in spinal fluid specimens

 

The following accompaniments should increase of suspicion for autoimmune encephalopathy:

-Headache

-Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)

-History of cancer

-Smoking history (20+ pack years) or other cancer risk factors

-Inflammatory cerebral spinal fluid (or isolated protein elevation)

-Neuroimaging signs suggesting inflammation

 

Evaluating limbic encephalitis (noninfectious)

 

Directing a focused search for cancer

 

Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect

Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test IDReporting NameAvailable SeparatelyAlways Performed
AEECIEncephalopathy, Interpretation, CSFNoYes
NMDCCNMDA-R Ab CBA, CSFNoYes
VGKCCVGKC-complex Ab IPA, CSFNoYes
LG1CCLGI1-IgG CBA, CSFNoYes
CS2CCCASPR2-IgG CBA, CSFNoYes
GD65CGAD65 Ab Assay, CSFYesYes
GABCCGABA-B-R Ab CBA, CSFNoYes
AMPCCAMPA-R Ab CBA, CSFNoYes
ANN1CAnti-Neuronal Nuclear Ab, Type 1NoYes
ANN2CAnti-Neuronal Nuclear Ab, Type 2NoYes
ANN3CAnti-Neuronal Nuclear Ab, Type 3NoYes
AGN1CAnti-Glial Nuclear Ab, Type 1NoYes
PCA1CPurkinje Cell Cytoplasmic Ab Type 1NoYes
PCA2CPurkinje Cell Cytoplasmic Ab Type 2NoYes
PCTRCPurkinje Cell Cytoplasmc Ab Type TrNoYes
AMPHCAmphiphysin Ab, CSFNoYes
CRMCCRMP-5-IgG, CSFNoYes

Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
WBNCParaneoplas Autoantibody WBlot,CSFNoNo
CRMWCCRMP-5-IgG Western Blot, CSFYesNo
ABLTCAmphiphysin Western Blot, CSFNoNo
NMOFCNMO/AQP4 FACS, CSFYesNo
NMOTCNMO/AQP4 FACS Titer, CSFNoNo
AMPICAMPA-R Ab IF Titer Assay, CSFNoNo
GABICGABA-B-R Ab IF Titer Assay, CSFNoNo
NMDICNMDA-R Ab IF Titer Assay, CSFNoNo

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

If indirect immunofluorescence assay (IFA) (ANN1C, ANN2C, ANN3C, AGN1C, PCA2C, PCTRC, AMPHC, CRMC) is indeterminate, then WBNC is performed at an additional charge.

 

If client requests or if IFA patterns suggest CRMP-5-IgG, then CRMWC is performed at an additional charge.

 

If IFA pattern suggest amphiphysin antibody, then ABLTC is performed at an additional charge.

 

If IFA pattern suggest NMO/AQP4-IgG, then NMOFC is performed at an additional charge.

 

If NMO/AQP4-IgG FACS screen assay requires further investigation, then NMO/AQP4-IgG FACS titration assay is performed at an additional charge.

 

If IFA pattern suggest AMPA-R Ab and AMPCC is positive, then AMPIC is performed at an additional charge.

 

If IFA pattern suggest GABA-B-R Ab and GABCC is positive, then GABIC is performed at an additional charge.

 

If IFA pattern suggest NMDA-R Ab and NMDCC is positive, then NMDIC is performed at an additional charge.

 

See Encephalopathy Autoimmune Evaluation Algorithm, Spinal Fluid in Special Instructions

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

ANN1C, ANN2C, ANN3C, AGN1C, PCA1C, PCA2C, PCTRC, AMPHC, CRMC, AMPIC, GABIC, NMDIC: Indirect Immunofluorescence Assay (IFA)

AMPCC, GABCC, NMDCC, LG1CC, CS2CC: Cell-Binding Assay (CBA)

GD65C: Immunoprecipitation Assay

VGKCC: Radioimmunoassay (RIA)

WBNC, ABLTC: Western Blot

AEECI: Interpretive Comments

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Encephalopathy-Autoimmune Eval, CSF

Aliases Lists additional common names for a test, as an aid in searching

AMPA-R Antibody CBA
Amphiphysin Antibody
Anti-Glial Nuclear Antibody, Type 1
Anti-Neuronal Nuclear Antibody, Type 1
Anti-Neuronal Nuclear Antibody, Type 2
Anti-Neuronal Nuclear Antibody, Type 3
Behavioral Change
Confusion
CRMP-5-IgG
ENCEC_x
Encephalitis
GABA-B-R Antibody CBA
Glutamic Acid Decarboxylase (GAD65)
NMDA-R Antibody CBA
Psychosis
Purkinje Cell Cytoplasmic Antibody, Type 1
Purkinje Cell Cytoplasmic Antibody, Type 2
Purkinje Cell Cytoplasmic Antibody, Type Tr
VGKC-Complex Antibody IPA
LGI1-IgG
CASPR2-IgG
Contactin-Associated Protein-Like-2 (CASPR2)-IgG
Leucine-Rich Glioma Inactived Protein-1 IgG